News

Boston Scientific has received CE mark for its Promus Element Everolimus-Eluting Coronary Stent System (PEEECSS), the company’s third-generation drug-eluting stent (DES) technology. Boston Scientific will begin marketing the

Caliper Life Sciences presented the benefits of the LabChipGX platform for high throughput screening and characterization assays for biological drugs at a training session for reviewers from the

Nuevolution has received a milestone payment derived from its collaboration with Merck & Co. The payment was triggered following identification of several candidate molecules that conformed to the

Bristol-Myers Squibb and ZymoGenetics have released final results from phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naive hepatitis C virus (HCV) patients.

Quintiles has entered into a strategic alliance with Eisai, to develop six potential oncology products in Eisai’s R&D pipeline. Under the terms of the agreement, Quintiles’ oncology experts

Bristol-Myers Squibb has reported 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis. According to the data Baraclude demonstrated greater viral suppression

Gilead Sciences has presented its three-year open label data from two pivotal phase III clinical trials, studies 102 and 103, evaluating the safety and efficacy of once-daily Viread

Amylin Pharmaceuticals (Amylin) and Eli Lilly have reported that the FDA has approved an expanded indication for Byetta (exenatide) injection. Byetta is now approved for use as a

Eli Lilly and Company (Lilly) has opened a new biotechnology center on the West Coast to discover and develop more biotechnology medicines. The Lilly Biotechnology Center – San